{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:10:38Z","timestamp":1790356238257,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046721"],"award-info":[{"award-number":["R01DA046721"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA040636"],"award-info":[{"award-number":["R01DA040636"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Persons with an opioid use disorder (OUD) who were incarcerated face many challenges to remaining abstinent; concomitantly, opioid-overdose is the leading cause of death among this population, with the initial weeks following release proving especially fatal. Extended-release naltrexone (XR-NTX) is the most widely-accepted, evidence-based OUD pharmacotherapy in criminal justice settings, and ensures approximately 30\u00a0days of protection from opioid overdose. The high cost of XR-NTX serves as a barrier to uptake by many prison\/jail systems; however, the cost of the medication should not be viewed in isolation. Prison\/jail healthcare budgets are ultimately determined by policymakers, and the benefits\/cost-offsets associated with effective OUD treatment will directly and indirectly affect their overall budgets, and society as a whole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This protocol describes a study funded by the National Institute of Drug Abuse (NIDA) to: evaluate changes in healthcare utilization, health-related quality-of-life, and other resources associated with different strategies of XR-NTX delivery to persons with OUD being released from incarceration; and estimate the relative \u201cvalue\u201d of each strategy. Data from two ongoing, publicly-funded, randomized-controlled trials will be used to evaluate these questions. In Study A, (XR-NTX Before vs. After Reentry), participants are randomized to receive their first XR-NTX dose before release, or at a nearby program post-release. In Study B, (enhanced XR-NTX vs. XR-NTX), both arms receive XR-NTX prior to release; the enhanced arm receives mobile medical (place of residence) XR-NTX treatment post-release, and the XR-NTX arm receives referral to a community treatment program post-release. The economic data collection instruments required to evaluate outcomes of interest were incorporated into both studies from baseline. Moreover, because the same instruments are being used in both trials on comparable populations, we have the opportunity to not only assess differences in outcomes between study arms within each trial, but also to merge the data sets and test for differences across trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Initiating XR-NTX for OUD prior to release from incarceration may improve patient health and well-being, while also producing downstream cost-offsets. This study offers the unique opportunity to assess the effectiveness and cost-effectiveness of multiple strategies, according to different stakeholder perspectives.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13722-020-00188-5","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:02:39Z","timestamp":1587574959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-0670","authenticated-orcid":false,"given":"Sean M.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina A.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Vocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Woody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"188_CR1","volume-title":"Results from the 2016 National Survey on Drug Use and Health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2017","unstructured":"Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2017."},{"key":"188_CR2","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 1999\u20132017. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics. Contract No.: NCHS Data Brief, no 329; 2018."},{"issue":"4","key":"188_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367.","journal-title":"Pain Med."},{"issue":"1\u20132","key":"188_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addbeh.2010.08.028","volume":"36","author":"RF Catalano","year":"2011","unstructured":"Catalano RF, White HR, Fleming CB, Haggerty KP. Is nonmedical prescription opiate use a unique form of illicit drug use? Addict Behav. 2011;36(1\u20132):79\u201386.","journal-title":"Addict Behav"},{"issue":"2","key":"188_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0376-8716(00)00162-9","volume":"61","author":"TL Mark","year":"2001","unstructured":"Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depen. 2001;61(2):195\u2013206.","journal-title":"Drug Alcohol Depen."},{"issue":"1","key":"188_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2989\/17280583.2013.849607","volume":"26","author":"SM Murphy","year":"2014","unstructured":"Murphy SM, McPherson S, Robinson K. Nonmedical prescription opioid use and violent behavior among adolescents. J Child Adolesc Mental Health. 2014;26(1):35\u201347.","journal-title":"J Child Adolesc Mental Health."},{"issue":"9","key":"188_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","volume":"34","author":"SM Murphy","year":"2016","unstructured":"Murphy SM, Polsky D. Economic evaluations of opioid use disorder interventions: a systematic review. Pharmacoeconomics. 2016;34(9):863\u20137.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"188_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/appi.ajp.2009.09081087","volume":"167","author":"WM Compton","year":"2010","unstructured":"Compton WM, Dawson D, Duffy SQ, Grant BF. The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States. Am J Psychiatry. 2010;167(4):473\u20135.","journal-title":"Am J Psychiatry."},{"key":"188_CR9","first-page":"1","volume-title":"Treating addicted offenders: a continuum of effective practices","author":"G Field","year":"2004","unstructured":"Field G. Continuity of offender treatment: from the institution to the community. In: Knight K, Farabee D, editors. Treating addicted offenders: a continuum of effective practices. Kingston: Civic Research Institute; 2004. p. 1\u20139."},{"issue":"4","key":"188_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1037\/0022-0167.54.4.466","volume":"54","author":"VA Shivy","year":"2007","unstructured":"Shivy VA, Wu JJ, Moon AE, Mann SC, Holland JG, Eacho C. Ex-offenders reentering the workforce. J Counsel Psychol. 2007;54(4):466.","journal-title":"J Counsel Psychol."},{"issue":"24","key":"188_CR11","doi-asserted-by":"publisher","first-page":"6583","DOI":"10.1523\/JNEUROSCI.1544-06.2006","volume":"26","author":"ND Volkow","year":"2006","unstructured":"Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Childress A-R, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24):6583\u20138.","journal-title":"J Neurosci."},{"issue":"6","key":"188_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/add.12894","volume":"110","author":"JD Lee","year":"2015","unstructured":"Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008\u201314.","journal-title":"Addiction"},{"issue":"2","key":"188_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugalcdep.2007.05.022","volume":"91","author":"TW Kinlock","year":"2007","unstructured":"Kinlock TW, Gordon MS, Schwartz RP, O\u2019Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depen. 2007;91(2):220\u20137.","journal-title":"Drug Alcohol Depen."},{"issue":"9","key":"188_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","volume":"159","author":"IA Binswanger","year":"2013","unstructured":"Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592\u2013600.","journal-title":"Ann Intern Med"},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.drugalcdep.2018.04.034","volume":"189","author":"LN Pizzicato","year":"2018","unstructured":"Pizzicato LN, Drake R, Domer-Shank R, Johnson CC, Viner KM. Beyond the walls: risk factors for overdose mortality following release from the philadelphia department of prisons. Drug Alcohol Depen. 2018;189:108\u201315.","journal-title":"Drug Alcohol Depen."},{"issue":"9","key":"188_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","volume":"108","author":"SI Ranapurwala","year":"2018","unstructured":"Ranapurwala SI, Shanahan ME, Alexandridis AA, Proescholdbell SK, Naumann RB, Edwards D Jr, et al. Opioid overdose mortality among former North Carolina inmates: 2000\u20132015. Am J Public Health. 2018;108(9):1207\u201313.","journal-title":"Am J Public Health"},{"key":"188_CR17","doi-asserted-by":"crossref","DOI":"10.1093\/wentk\/9780190916039.001.0001","volume-title":"The opioid epidemic: what everyone needs to know","author":"Y Olsen","year":"2019","unstructured":"Olsen Y, Sharfstein JM. The opioid epidemic: what everyone needs to know. New York: Oxford University Press; 2019."},{"key":"188_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","volume":"142","author":"MS Gordon","year":"2014","unstructured":"Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O\u2019Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depen. 2014;142:33\u201340.","journal-title":"Drug Alcohol Depen."},{"issue":"1","key":"188_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","volume":"99","author":"S Magura","year":"2009","unstructured":"Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depen. 2009;99(1):222\u201330.","journal-title":"Drug Alcohol Depen."},{"issue":"7","key":"188_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1176\/appi.ajp.2008.07111835","volume":"165","author":"KM Carroll","year":"2008","unstructured":"Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA, Nuro KF, et al. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry. 2008;165(7):881\u20138.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"188_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jsat.2009.03.002","volume":"37","author":"TW Kinlock","year":"2009","unstructured":"Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O\u2019Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12\u00a0months postrelease. J Subst Abuse Treat. 2009;37(3):277\u201385.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"188_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08897077.2014.902787","volume":"36","author":"MS Gordon","year":"2015","unstructured":"Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O\u2019Grady KE, et al. Buprenorphine treatment for probationers and parolees. Subst Abus. 2015;36(2):217\u201325.","journal-title":"Subst Abus."},{"issue":"1","key":"188_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","volume":"105","author":"A Nunn","year":"2009","unstructured":"Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depen. 2009;105(1):83\u20138.","journal-title":"Drug Alcohol Depen."},{"issue":"3","key":"188_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/jurban\/jti072","volume":"82","author":"JD Rich","year":"2005","unstructured":"Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82(3):411\u20139.","journal-title":"J Urban Health."},{"key":"188_CR25","doi-asserted-by":"publisher","DOI":"10.1037\/e560272006-001","volume-title":"Drug use and dependence, state and federal prisoners, 2004","author":"CJ Mumola","year":"2006","unstructured":"Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004. Washington, D.C.: Department of Justice, Programs OoJ; 2006."},{"issue":"1","key":"188_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/08897077.2011.611460","volume":"33","author":"PD Friedmann","year":"2012","unstructured":"Friedmann PD, Hoskinson R Jr, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9\u201318.","journal-title":"Subst Abus."},{"key":"188_CR27","unstructured":"Substance Abuse and Mental Health Services Administration. Medication Assisted Treatment. 2016. http:\/\/www.samhsa.gov\/medication-assisted-treatment."},{"issue":"12","key":"188_CR28","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","volume":"36","author":"N Krawczyk","year":"2017","unstructured":"Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff. 2017;36(12):2046\u201353.","journal-title":"Health Aff."},{"key":"188_CR29","unstructured":"Medication-assisted treatment for opioid addiction. Office of National Drug Control Policy; 2012."},{"key":"188_CR30","unstructured":"Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2004."},{"key":"188_CR31","unstructured":"IBM Micromedex\u00ae RED BOOK\u00ae (electronic version). Red Book Greenwood Village, Colorado: IBM Watson Health; 2019. https:\/\/www.micromedexsolutions.com\/."},{"key":"188_CR32","unstructured":"U.S. Department of Veterans Affairs Federal Supply Schedule Services 2019. https:\/\/www.fss.va.gov."},{"key":"188_CR33","volume-title":"Red Book: Pharmacy\u2019s Fundamental Reference","author":"Physician\u2019s Desk Reference","year":"2010","unstructured":"Physician\u2019s Desk Reference. Red Book: Pharmacy\u2019s Fundamental Reference. Montvale: Thomson Reuters; 2010."},{"key":"188_CR34","unstructured":"The Pew Charitable Trusts. Prison Health Care: Costs and Quality. 2017."},{"issue":"1","key":"188_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-12-111","volume":"12","author":"A H\u00e5kansson","year":"2012","unstructured":"H\u00e5kansson A, Berglund M. Risk factors for criminal recidivism\u2013a prospective follow-up study in prisoners with substance abuse. BMC Psychiatry. 2012;12(1):1.","journal-title":"BMC Psychiatry."},{"key":"188_CR36","volume-title":"Recidivism of prisoners released in 30 states in 2005 patterns from 2005 to 2010","author":"MR Durose","year":"2014","unstructured":"Durose MR, Cooper AD, Snyder HN. Recidivism of prisoners released in 30 states in 2005 patterns from 2005 to 2010, vol. 28. Washington, DC: Bureau of Justice Statistics; 2014."},{"key":"188_CR37","volume-title":"Cost-effectiveness in health and medicine","author":"PJ Neumann","year":"2017","unstructured":"Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2017.","edition":"2"},{"key":"188_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199685028.001.0001","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2014","unstructured":"Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2014."},{"key":"188_CR39","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Schulpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"issue":"8","key":"188_CR40","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/add.13807","volume":"112","author":"SM Murphy","year":"2017","unstructured":"Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, et al. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal-justice-involved persons with a history of opioid use disorder. Addiction. 2017;112(8):1440\u201350.","journal-title":"Addiction"},{"issue":"13","key":"188_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","volume":"374","author":"JD Lee","year":"2016","unstructured":"Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232\u201342.","journal-title":"N Engl J Med"},{"issue":"4","key":"188_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1017\/S0266462300007121","volume":"7","author":"MF Drummond","year":"1991","unstructured":"Drummond MF, Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care. 1991;7(4):561\u201373.","journal-title":"Int J Technol Assess Health Care"},{"key":"188_CR43","volume-title":"Drug Abuse Treatment Cost Anslysis Program (DATCAP): User\u2019s Manual","author":"MT French","year":"2003","unstructured":"French MT. Drug Abuse Treatment Cost Anslysis Program (DATCAP): User\u2019s Manual. Florida: University of Miami; 2003."},{"issue":"5","key":"188_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0740-5472(97)00132-3","volume":"14","author":"MT French","year":"1997","unstructured":"French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat. 1997;14(5):445\u201355.","journal-title":"J Subst Abuse Treat"},{"key":"188_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, editors. Measuring Alcohol Consumption. Berlin: Springer; 1992. p. 41\u201372."},{"key":"188_CR46","doi-asserted-by":"crossref","unstructured":"Brown JB, Adams ME. Patients as reliable reporters of medical care process: recall of ambulatory encounter events. Med Care. 1992:400\u201311.","DOI":"10.1097\/00005650-199205000-00003"},{"issue":"2","key":"188_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.aje.a115129","volume":"129","author":"SD Harlow","year":"1989","unstructured":"Harlow SD, Linet MS. Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol. 1989;129(2):233\u201348.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"188_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0895-4356(96)00143-6","volume":"49","author":"RO Roberts","year":"1996","unstructured":"Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol. 1996;49(9):989\u201395.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"188_CR49","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/00005650-199907000-00006","volume":"37","author":"DB Wallihan","year":"1999","unstructured":"Wallihan DB, Stump TE, Callahan CM. Accuracy of self-reported health services use and patterns of care among urban older adults. Med Care. 1999;37(7):662\u201370.","journal-title":"Med Care"},{"key":"188_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugalcdep.2016.01.021","volume":"161","author":"SM Murphy","year":"2016","unstructured":"Murphy SM, Campbell AN, Ghitza UE, Kyle TL, Bailey GL, Nunes EV, et al. Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial. Drug Alcohol Depen. 2016;161:119\u201326.","journal-title":"Drug Alcohol Depen."},{"key":"188_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","volume":"170","author":"SM Murphy","year":"2019","unstructured":"Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, et al. Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse. Ann Intern Med. 2019;170:90\u20138.","journal-title":"Ann Intern Med"},{"issue":"9","key":"188_CR52","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","volume":"105","author":"D Polsky","year":"2010","unstructured":"Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine\u2013naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616\u201324.","journal-title":"Addiction"},{"issue":"7","key":"188_CR53","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/cid\/ciz384","volume":"70","author":"S Gutkind","year":"2019","unstructured":"Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, et al. Cost-effectiveness of HCV treatment models for people who inject drugs in opioid agonist treatment programs. Clin Infect Dis. 2019;70(7):1397\u2013405.","journal-title":"Clin Infect Dis."},{"issue":"11","key":"188_CR54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"3","key":"188_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"188_CR56","unstructured":"EuroQol. EQ-5D 2019. https:\/\/euroqol.org."},{"key":"188_CR57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/B978-0-12-375678-7.00505-8","volume-title":"Encylopedia of Health Economics","author":"J Richardson","year":"2014","unstructured":"Richardson J, Mckie J, Bariola E. Multiattribute utility instruments and their use. In: Culyer AJ, editor. Encylopedia of Health Economics. Amsterdam: Elsevier; 2014. p. 341\u201357."},{"key":"188_CR58","volume-title":"Comparison of self-report and official data for measuring crime. Measurement problems in criminal justice research: Workshop summary","year":"2003","unstructured":"Thornberry TP, Krohn MD, editors. Comparison of self-report and official data for measuring crime. Measurement problems in criminal justice research: Workshop summary. Washington, DC: National Academies Press; 2003."},{"issue":"3\u20134","key":"188_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1300\/J076v30n03_07","volume":"30","author":"K Nieves","year":"2000","unstructured":"Nieves K, Draine J, Solomon P. The validity of self-reported criminal arrest history among clients of a psychiatric probation and parole service. J Offender Rehabil. 2000;30(3\u20134):133\u201351.","journal-title":"J Offender Rehabil."},{"issue":"1","key":"188_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-244X-8-2","volume":"8","author":"I Jansson","year":"2008","unstructured":"Jansson I, Hesse M, Fridell M. Validity of self-reported criminal justice system involvement in substance abusing women at 5-year follow-up. BMC Psychiatry. 2008;8(1):2.","journal-title":"BMC Psychiatry."},{"issue":"1","key":"188_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40352-018-0073-6","volume":"6","author":"KE McCollister","year":"2018","unstructured":"McCollister KE, Yang X, Murphy SM, Leff JA, Kronmal RA, Chandler RK, et al. Criminal justice measures for economic data harmonization in substance use disorder research. Health Justice. 2018;6(1):17.","journal-title":"Health Justice"},{"issue":"3","key":"188_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199\u2013213.","journal-title":"J Subst Abuse Treat"},{"key":"188_CR63","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"188_CR64","unstructured":"Centers for Medicare & Medicaid Services. Transformed Medicaid Statistical Information System (T-MSIS) 2020. https:\/\/www.medicaid.gov\/medicaid\/data-and-systems\/macbis\/tmsis\/index.html]."},{"key":"188_CR65","volume-title":"Medicare hospital prospective payment system: how DRG rates are calculated and updated","author":"T Brady","year":"2001","unstructured":"Brady T, Robinson B. Medicare hospital prospective payment system: how DRG rates are calculated and updated. Washington, D.C.: Health and Human Services Office of Inspector General, Office of Evaluations and Inspections; 2001."},{"issue":"1\u20132","key":"188_CR66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drugalcdep.2009.12.002","volume":"108","author":"KE McCollister","year":"2010","unstructured":"McCollister KE, French MT, Fang H. The cost of crime to society: new crime-specific estimates for policy and program evaluation. Drug Alcohol Depen. 2010;108(1\u20132):98\u2013109.","journal-title":"Drug Alcohol Depen."},{"key":"188_CR67","unstructured":"Bureau of Labor Statistics. Occupational Outlook Handbook Washington, DC2018http:\/\/www.bls.gov\/ooh\/home.htm."},{"key":"188_CR68","volume-title":"The causal effect of education on earnings","year":"1999","unstructured":"Card D, editor. The causal effect of education on earnings. Oxford: Elsevier; 1999."},{"key":"188_CR69","unstructured":"Max W, Rice DP, Sung H-Y, Michel M. Valuing human life: estimating the present value of lifetime earnings, 2000. University of California San Francisco: Center for Tobacco Control Research and Education; 2004."},{"issue":"4","key":"188_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","volume":"46","author":"RS Braithwaite","year":"2008","unstructured":"Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349\u201356.","journal-title":"Med Care"},{"issue":"9","key":"188_CR71","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"6719","key":"188_CR72","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","volume":"300","author":"JNS Matthews","year":"1990","unstructured":"Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Brit Med J. 1990;300(6719):230\u20135.","journal-title":"Brit Med J."},{"issue":"7","key":"188_CR73","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1046\/j.1360-0443.2000.9579993.x","volume":"95","author":"HD Holder","year":"2000","unstructured":"Holder HD, Cisler RA, Longabaugh R, Stout RL, Treno AJ, Zweben A. RESEARCH REPORT alcoholism treatment and medical care costs from project MATCH. Addiction. 2000;95(7):999\u20131013.","journal-title":"Addiction"},{"key":"188_CR74","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2005."},{"key":"188_CR75","unstructured":"Vestal C. New momentum for addiction treatment behind bars. PEW; 2018."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-020-00188-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-020-00188-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-020-00188-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:09:12Z","timestamp":1722776952000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-020-00188-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/s13722-020-00188-5","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Murphy reports grants from NIH during the conduct of the study, and having consulted for Sandoz Inc. outside the submitted work. Authors not named here have disclosed no conflicts of interest. Drs. Gordon and Woody are receiving in-kind study drug from Alkermes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}